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Abstract
Background and Aims: Cardiovascular complications are major causes of morbidity and mortality in 
patients with autosomal dominant polycystic kidney disease (ADPKD). In particular, hypertension 
is insidious and remains a continuous problem that evolves during the course of the disease. Hy-
pertension in ADPKD has been associated with abnormality in the renin-angiotensin-aldosterone 
system (RAAS). Early vascular changes have also been reported in young ADPKD patients. In 
addition, the cellular functions of mechanosensory cilia within vascular system have emerged 
recently. The basic and clinical perspectives of RAAS, vascular remodeling and sensory cilia are 
reviewed with regard to hypertension in ADPKD.
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Introduction 
Autosomal dominant polycystic kidney disease 
(ADPKD) is a systemic hereditary disorder that af-
fects more than 12.5 million individuals worldwide. 
Thus, ADPKD is the most common life-threatening 
hereditary genetic disease, compared to the numbers 
of individuals affected by cystic fibrosis, Downs 
syndrome, hemophilia, muscular dystrophy, and 
sickle cell anemia, combined (1, 2). Approximately 
600,000 Americans have the disease, and the preva-
lence of the disease varies between 1:400 and 1: 
1000 in the general population (3, 4).
ADPKD is characterized by a long course of 
normal glomerular filtration rate (GFR), micro-
albuminuria and early development of hyperten-
sion, followed by a persistent decrease in GFR in 
the fifth to sixth decades. This eventually leads to 
end stage renal disease in approximately 50% of 
patients (5, 6). Although the kidneys are the major 
sites of clinical disease (Figure 1), the prevalence of 
extrarenal manifestations in ADPKD is high.  These 
extrarenal manifestations include cyst formation 
in other ductal organs and various cardiovascular 
abnormalities (7-11). Cardiovascular abnormalities 
may include hypertension, cerebral and coronary 
artery aneurysms, mitral valve prolapse, aortic root 
dilation, dissection of the thoracic aorta, aneurysm 
formation in the abdominal aorta, vascular ectasia, 
and abnormal function of the microvascular bed 
(12-15).
The frequencies of extrarenal manifestations of 
ADPKD include hypertension (78%), hepatic cysts 
(75%), diverticulosis (70%), ovarian cysts (40%), 
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cardiac valve disorders (25%), inguinal hernias (15%) 
and intracranial aneurysms (10%) (16). Prevalence 
of intracranial aneurysms in ADPKD individuals 
is increased several folds compared to the general 
population (4.0-11.7% versus 1.0%) and intracranial 
aneurysm rupture remains a devastating complica-
tion in ADPKD (17). Screening ADPKD individuals 
with a family history of sub-arachnoid hemorrhage 
is thus essential, because intracranial aneurysms ap-
pears to cluster in ADPKD families with history of 
cerebral hemorrhage (18). A retrospective study of 
77 ADPKD individuals with aneurysms showed that 
only 29% were normotensive within one year prior 
to rupture (19). In particular, renal function was nor-
mal in half of these patients. Therefore, hypertension 
is an associated finding in these individuals. More 
important, hypertension has been a continual risk 
factor for cardiovascular diseases in ADPKD (15). 
It occurs early in ADPKD individuals, compared 
to their age-matched cohorts and remains the most 
frequent cause of mortality (12).
The discovery of the PKD1 and PKD2 genes has 
opened up avenues of research in molecular biology 
to further understand the role of genetic mutations 
in the pathogenesis of this devastating disease. 
PKD1 encodes for polycystin-1, which is involved 
in the mechanosensory function, and polycystin-2 
encoded by PKD2 is a sensory calcium channel (20-
29). The PKD1 mutation affects nearly 85% of the 
patients with ADPKD, and they have a shorter and 
more severe disease progressions than patients with 
PKD2 mutation; i.e. 54 years compared to 74 years, 
respectively (30). 
While numerous progresses have been reported 
about the pathology and pathogenesis of cystic 
kidneys (31), this article is intended to review the 
hypertension aspect of ADPKD. In particular, sev-
eral ideas of “cilia hypothesis” have been discussed 
regarding polycystic kidneys (32-36). These ideas 
will be revisited to understand the constituents of the 
cardiovascular complications, such as hypertension, 
Figure 1. Autosomal dominant polycystic kidney
a.  Polycystic kidney is characterized by the presence of 
numerous fluid-filled cysts.  An ADPKD kidney can reach 
over 10 inches in length, about 3-4 times larger than a normal 
four-inch long kidney.  b.  Fluid accumulation in the cysts 
contributes to the weight and size of an ADPKD kidney.  c.  In 
contrast to heavier tissue mass in renal carcinoma, an ADPKD 
kidney could lose about 7-28 ounces of weight after fluid cyst 
removal.  This is an important phenotypic characteristic that 
despite its large size and volume, an ADPKD kidney actually 
contains equal or less tissue mass than a normal kidney.
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with respect to the new clinical and basic science 
development in ADPKD. 
Pathogenesis of hypertension in ADPKD
Progressive enlargement of cysts by magnetic 
resonance imaging, as studied in the recent CRISP 
(The consortium for radiologic imaging studies of 
polycystic kidney disease) trial and other studies, 
has been linked to deterioration of renal function 
in ADPKD (6, 37, 38). These studies have shown 
that renal function remains relatively stable until the 
renal volume reaches 1500 cm3, at which point there 
is a rapid decline that necessitates renal replacement 
therapy (39). It is believed that distortion of the renal 
architecture leads to structural damage and tubular 
dysfunction and results in activation of the renin-
angiotensin-aldosterone system (RAAS). These 
findings have also been reported in hypertensive 
animal models of polycystic kidney disease (40, 
41). This mechanism, which is well documented 
in the clinical course of this disease (42), has also 
been proposed to contribute to the increased blood 
pressure seen early in ADPKD patients.  Changes 
in the vasculatures during the course of the disease 
progression have also been observed in both human 
(43-47) and animal (48-52) studies. Most recently, 
ciliary defects have also been proposed to cause the 
complication of hypertension in ADPKD (20, 25). 
We will therefore look at these possibilities as the 
origins of hypertension in ADPKD.
Renin-angiotensin system
Compared with age-matched healthy control sub-
jects, an increase in intrarenal RAAS activity is seen 
in ADPKD patients, regardless of their blood pressure 
and renal function (53). Angiotensin II has been im-
plicated in the development of vascular hypertrophy, 
resulting in structural remodeling (54). Angiotensin 
II generation via ACE-independent chymase-like 
pathways has been shown in ADPKD kidneys, 
making it an attractive target for pharmacological 
intervention (Figure 2). Control of blood pressure in 
most renal diseases has shown benefit to slow the 
decline in renal function. In particular, the use of 
angiotensin converting enzyme inhibitors (ACE-I) 
and angiotensin receptor blockers (ARB) to block 
the RAAS has shown additional benefits (55, 56). 
Although many clinical trials have been undertaken 
to halt the progression of renal failure by optimal 
control of blood pressure and micro-albuminuria 
with RAAS blockade, there has been no data to show 
significant decrease in the inevitable progression to 
renal failure (57, 58). However, there is a general 
consensus that early identification of ADPKD indi-
viduals and achieving optimal blood pressure control 
with ACE-I and other agents remain crucial in pre-
venting the cardiovascular morbidity and mortality 
associated with this disease (59).  
Studies which included ambulatory blood pressure 
monitoring have shown that in children and young 
adults with ADPKD, increases in left ventricular 
mass index occurred earlier than changes in renal 
volume in the hypertensive and borderline hyper-
tensive group (60). In addition, the most significant 
finding was that even among the normotensive 
children, higher indices were noted in those within 
the upper quartile of the normal blood pressure. This 
suggests that cardiovascular organs remain vulner-
able targets in ADPKD patients, even in the early 
stages of the disease.
Interestingly, the likelihood of hypertension in 
ADPKD patients is significantly greater when the 
affected parent was hypertensive (61). Thus, the 
family history is especially critical in this case, 
although it is not immediately understood whether 
this association is related to genetic modifiers or 
polymorphisms with regards to RAAS (62). One 
caveat is that pharmacological agents prescribed to 
inhibit RAAS result in incomplete inhibition of the 
RAAS. Angiotensin II, for example, can be gener-
ated via multiple pathways (Figure 2). Consistent 
with this view, the inhibition of RAAS activation by 
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ACE inhibitors has not been always proven to retard 
the course of the disease, compared to results seen 
in renal diseases with primary glomerular injury 
(63). There are also other factors contributing to 
the increase in blood pressure. Tubular dysfunction 
caused by structural changes leading to retention 
of sodium and water and increased sympathetic 
activity, for example, is seen in ADPKD patients 
(64). Nonetheless, inhibition of RAAS activation 
might provide a logical way to reduce factors that 
contribute to the propensity for high blood pressure 
in ADPKD (Figure 2).
Vascular remodeling
There is growing evidence in literature that once 
a change in GFR is observed, extensive vascular re-
modeling has already occurred (43-47). Scientists and 
clinicians have been focusing their efforts on charac-
terizing early biomarkers of injury. Increased urinary 
excretion of MCP-1 (monocyte chemoattractant 
protein-1) in adult patients with ADPKD has been 
reported, and microalbuminuria has been established 
as a frequent sign of progression of the disease (65, 
66). Recently, changes in vascular remodeling with 
altered intima-media thickness of carotid arteries 
(CIMT), impaired endothelial-dependent vascular 
relaxation (EDVR) and vascular ultrasound thick-
ness have been reported in ADPKD patients (15, 45, 
47, 67-70). CIMT in hypertensive ADPKD patients 
and patients with essential hypertension was sig-
nificantly greater than that of normotensive ADPKD 
patients and healthy subjects. In addition, CIMP 
in normotensive ADPKD patients is significantly 
greater than in healthy subjects. 
Polycystin-1 and polycystin-2 are expressed 
in vascular smooth muscle cells (71, 72). These 
proteins have an important role in maintaining the 
integrity of dense plaques of the arterial wall (73). 
Aortic root dilatation is a known finding in patients 
with ADPKD, and aortic dissection is a known extra 
Figure 2. Hypertension in polycystic kidney disease
Renal cysts are thought to compress and disrupt the vascular network in the kidney.  The kidney would then become ischemic, 
which would induce renin release from the juxtaglomerular apparatus.  The increase in renin secretion could accelerate the 
conversion of angiotensinogen to angiotensin I, which is converted by angiotensin converting enzyme (ACE) to angiotension 
II.  Activation of angiotensin receptor (AT1) would initiate cascades of physiological responses that would lead to hyperten-
sion.  Additional secondary pathways exist in converting angiotensinogen to angitotensin II.  As indicated by the light arrows, 
these secondary pathways involve chymase, tonin and/or cathepsin G.
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renal complication in these patients (7). Altered 
expression of polycystins in arterial smooth muscle 
cells, together with collagen disruption and cystic de-
generation, has been seen in histological specimens 
of aortic dissections and cerebral aneurysms from 
patients with ADPKD. It has further been reported 
that altered functional polycystins would result in 
various degrees of cardiovascular abnormalities 
(49-52). In addition to focal hemorrhage, altered 
polycystin function in the mouse model exhibits 
progressive total body edema, a feature of cardiac 
failure (52).
An important question that remains unanswered 
is whether or not changes in vasculature is a direct 
result of the enlargement of the kidney. Nonethe-
less it is known that the remodeling of vasculature 
is a counter beneficiary that can result in a more 
severe hypertension (74-76). Vascular remodeling 
in the arteries may develop through inward/outward 
hypotrophic or hypertrophic mechanisms (77). 
In either instance, vascular remodeling will place 
greater stress on the cardiovascular system.  In light 
of this view, several anti-proliferative therapies have 
been proposed as potential treatments in ADPKD. 
At present, however, the immediate impact of this 
therapy on blood pressure is still unknown.
Other contributing factors
Other factors that may contribute to cardiovascu-
lar hypertension in ADPKD include insulin resist-
ance, asymmetric dimethylarginine (ADMA), and 
vascular cilia dysfunction.
Numerous studies have shown a causal associa-
tion between insulin resistance or hyperinsulinemia 
and hypertension.  Insulin resistance and concomi-
tant hyperinsulinemia are present very early in the 
course of renal diseases including in ADPKD (78, 
79). Increased sympathetic activity present in in-
dividuals with chronic renal disease can contribute 
to derangements of glucose metabolism (80). Al-
though the mechanistic relationship between insulin 
resistance and polycystic kidney disease is not clear, 
the correlation between insulin resistance and left 
ventricular mass index in individuals with polycystic 
kidney disease has been shown to be independent of 
age, weight, systolic blood pressure and albuminuria 
(79). Thus, ADPKD patients with insulin resistance 
could have a more complex outcome on cardiovas-
cular complications. Insulin-mediated sodium reten-
tion, increased sympathetic activity, impairment of 
endothelial nitric oxide production and increased 
endothelin-1 secretion have been suggested to worsen 
vascular hypertension due to insulin resistance (81). 
However, their relevance with regards to polycystic 
kidney remains to be explored further.
To further examine endothelial function in 
ADPKD, the plasma concentrations of vasodilator 
nitric oxide were measured in twenty seven ADPKD 
patients and twenty seven healthy controls. In this 
study,  the plasma concentration of nitric oxide was 
shown to be reduced in ADPKD patients, confirming 
an association between ADPKD and endothelial dys-
function (82). To further substantiate the endothelial 
dysfunction in ADPKD, levels of ADMA (a marker 
of an inhibitor of nitric oxide synthase) were sig-
nificantly increased in patients with early ADPKD 
compared to healthy age-matched individuals (83). 
Although the significance of ADMA in ADPKD is 
not immediately understood, endothelia-dependent 
vasodilation offers substantial evidence which is too 
important to ignore.
Cilia and their functions have been reported to 
play essential roles in renal epithelial cells and in 
cystic kidney diseases. Vascular cells, too, have cilia 
(Figure 3). Endovascular cilia are thought to function 
as local regulators of blood vessel (20, 25, 84-87). 
Local regulation of blood vessels, also known as 
autoregulation, is a necessary mechanism to achieve 
immediate control of blood pressure within a region. 
Autoregulation is an effective and efficient way to 
control the amount of blood flow locally without 
altering the neighboring systems significantly (88).
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In the most recent studies within the cardiovascu-
lar field (20, 25), it is shown that each endothelial 
cell has one primary cilium, and shear stress that 
produces enough drag force on the cell surface 
is able to bend and “activate” the primary cilium 
(Figure 3). Although the biophysical properties of 
vascular cilia are less studied and not well known, 
it has been proposed that endothelial cilia are shear 
stress sensors (20, 25). In addition, when non-
ciliated cells are challenged with fluid-shear stress, 
they show significantly less induction of the shear 
marker Krüppel-Like Factor-2, as compared to 
ciliated endothelial cells (84, 86). Because primary 
cilia sense only a low range of fluid-shear stress, 
endothelial cells in vivo most likely project the cilia 
in the areas with more subtle shear stress. Consist-
ent with this idea, cilia in vascular endothelial cells 
disassemble after a long exposure to high fluid shear 
Figure 3. Primary cilia and hypertension
Primary cilia are believed to play significant roles in the formation of renal cysts and the development of hypertension in 
ADPKD.  a.  Within the lumen of a blood vessel, each vascular endothelial cell possesses one primary cilium, originated from 
the apical cell membrane.  Cilium is projected from “mother” centriole, which is also known as basal body.  Similar to their 
function in the renal tubule which is to sense urine flow, cilia in the endothelial lining of a vessel are hypothesized to sense 
blood flow (shear stress).  b.  Projecting into the lumen, cilia function like antennae to sense changes in blood flow or pressure. 
Femoral arteries from adult rodents were isolated and prepared for fluorescence imaging studies.  A segment of the artery 
was embedded in OCT solution, and sectioned at a thickness of 5 μm.  The image was taken at 10x to outline the embedded 
tissue.  c.  The embedded tissue was fixed and labeled with antibody against polaris, a structural protein for cilia.  The pres-
ence of cilia was observed using florescence imaging.  d, e.  Arterial segments from femoral arteries of adult rodents were 
cut open and coated with 10 μm of gold particles and analyzed with scanning electron microscopy.  White arrows indicate 
the presence of cilia.  f.  Upon sensing these changes, mechanosensory polycystins complex is activated.  This results in 
the influx of extracellular calcium that would initiate biochemical cascades that lead to production of NO vasodilator through 
endothelial nitric oxide (eNOS).  Activation of eNOS also depends on the contribution of calmodulin (CaM), phosphoinositide 
kinase-3 (PI3K) Akt/protein kinase B (PKB) in addition to calcium-dependent protein kinase (PKC).
International Journal of Nephrology & Urology, 2010; 2(2):294-308
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stress (89). Because atherosclerosis also develops in 
the arterial system at sites of low shear stress, cilia 
have been further proposed to play an important role 
in atherogenesis, a process of forming atheromas in 
the inner lining of arteries (87).
As micro-sensory compartments, ciliary functions 
depend on mechano-proteins such as polycystin-1 
and polycystin-2 (Figure 3). Thus, the overall func-
tions of these sensory compartments depend on both 
functional and structural cilia proteins. Within a 
blood vessel, an abrupt increase in blood pressure 
or shear stress can be detected by these sensory 
proteins localized in the cilia (20, 25). With cilia as 
a local regulatory mechanism, the extracellular fluid 
mechanics can then be transduced and translated into 
a complex of intracellular signaling, which in turn 
would activate eNOS - an endothelial enzyme that 
synthesizes nitric oxide (NO) gas. The release of NO 
from endothelial cells will diffuse to the neighboring 
smooth muscle cells, thereby, promoting vasodilation 
(90-92). The overall cilia dysfunction in ADPKD 
may thus result in an increased total peripheral re-
sistance, thereby increasing blood pressure.
Treatment of hypertension in ADPKD
Mutations in PKD1 and PKD2 have been sug-
gested to contribute to vascular hypertension (30, 
93, 94). This is probably due to failure to convert an 
increase in mechanical blood flow into cellular NO 
biosynthesis in order to control the vascular tone, i.e. 
blood pressure (20, 25). Of note is that hypertension 
occurs at a much earlier age in patients with ADPKD 
than in the general population (95). The median age 
of hypertension in ADPKD is about 30 years, com-
pared with a median age of 45-55 years in patients 
with essential hypertension (61). Hypertension oc-
curs in children even before they are diagnosed with 
ADPKD (96-99) or before any substantial reduction 
in glomerular filtration rate is observed (100, 101).
Uncontrolled hypertension can, in fact, dete-
riorate kidney function much faster.  In ADPKD, 
some studies have further suggested that high blood 
pressure would promote faster cyst growth (102, 
103). Early and effective treatments of hypertension 
become very important to decrease the morbidity 
and mortality of patients with ADPKD, including 
the dreaded complication of intracranial aneurysm 
ruptures (12, 97). Therefore, it makes sense to con-
trol the blood pressure in young ADPKD patients 
aggressively.
Antihypertensives
Studies in experimental models of polycystic kid-
ney disease have shown that the ACE-I enalapril or 
the ARB losartan are more effective in lowering blood 
pressure, maintaining renal volume and preserving 
renal function than hydralazine (104). Moreover, in 
a seven-year prospective study comparing rigorous 
versus standard blood pressure control, enalapril 
was found to be more effective than calcium chan-
nel blocker amlodipine in reducing left ventricular 
mass index (LVMI). However, none of these agents 
affects the rate of decline in renal function (105). 
Similarly, an atenolol-based regimen, compared to 
enalapril, showed no difference in decline of renal 
function over a three-year period (106). In a six 
months of follow-up study, ARB candesartan shows 
little change in blood pressure or renal progression 
in ADPKD patients (107). However, candesartan 
reduced excretion of urinary fatty acid binding 
protein, which has been reported to be higher in 
ADPKD patients.
It was also reported that muscle sympathetic 
nerve activity is increased in hypertensive patients 
with ADPKD, regardless of renal function (64, 108). 
This suggests that sympathetic hyperactivity could 
contribute to the pathogenesis of hypertension in 
ADPKD. However, it is not immediately understood 
whether the sensitivity to sympathetic nerve activity 
is a secondary effect due to an increase in RAAS 
system (Figure 2). Of apparent complexity is that 
angiotensin can stimulate the sympathetic nervous 
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system and that sympathetic nerve activity can 
also stimulate RAAS (109, 110). At least in murine 
models of PKD, bilateral renal denervation could 
reduce cystic kidney size, cyst volume and most 
importantly, systolic blood pressure (111). It is 
therefore very likely that sympathetic nerve activity 
would activate RAAS system, which would increase 
blood pressure.  
Regardless, in a 3-year prospective randomized 
double-blind study that compared ACE-I ramipril 
and the beta-blocker metoprolol as first line therapy 
in hypertensive ADPKD patients, no differences 
in renal function or LVMI were detected (112). 
However, LVMI increased in patients with standard 
blood pressure control while it remained stable or 
improved in patients with rigorous blood pressure 
control, suggesting that aggressive blood pressure 
control is necessary in ADPKD patients (113).
Aside from ACE-I, calcium channel blockers 
have also been reported to reduce blood pressure 
effectively and preserve renal function in ADPKD 
patients (114). A different study, however, showed 
that the renoprotective effect of ARB was consider-
ably more favorable than calcium channel blocker in 
the treatment of ADPKD (115). The use of diuretics 
in hypertensive ADPKD patients also results in a 
similar decrease in blood pressure, although they 
may promote a faster loss of renal function compared 
to ACE-I therapy (57). In addition, vasopressin V2 
receptor antagonists have been proposed to have 
anti-hypertensive effect (116), probably by reducing 
renal sodium reabsorption.
Although a definitive study to demonstrate effi-
cacy of ACE-I on renal progression in ADPKD is not 
available, there is a wealth of evidence that suggest 
ACE-I are beneficial in slowing renal progression in 
non-diabetic kidney disease. Clinical practice guide-
lines from the National Kidney Foundation and the 
Joint National Committee on Prevention Detection 
Evaluation and Treatment of High Blood Pressure 
call for ACE-I as the first line of agent for treatment of 
hypertension in patients with chronic kidney disease 
(117-119). Although ACE-I and ARB are considered 
first line agents to treat hypertension in ADPKD, 
caution needs to be used in pregnant women due to 
known birth defects and in advanced renal failure 
due to risk of life-threatening hyperkalemia. Overall, 
early and effective treatment of hypertension is very 
important to decrease the morbidity and mortality of 
patients with ADPKD.
Transplantation
Activation of the RAAS has been found in nor-
motensive and hypertensive ADPKD subjects. As 
cysts enlarge, they compress the renal vasculature 
and attenuate the renal vessels, causing intrarenal 
ischemia and activation of the RAAS (120-122). 
Since cardiovascular abnormalities are thought to 
initiate from the cystic kidneys in ADPKD, there has 
been a great interest in studying the outcomes after 
renal transplantation in these individuals. Earlier 
outcome studies in renal transplant recipients with 
ADPKD on azathiprine or cyclosporine immunosup-
pression have shown an increase in cardiovascular 
morbidity compared to non-ADPKD transplant 
recipients (123). However, cardiovascular events, 
graft and patient survival up to 10 years of follow-up 
were not found to be significantly different between 
transplant recipients with ADPKD and non-diabetic 
transplant recipients (124). The severity, rather than 
occurrence, of urinary tract infections are more sig-
nificant in post-transplant recipients with ADPKD 
compared to their non-diabetic cohorts (124). 
In a different report of eleven transplant cases 
in hypertensive ADPKD, six patients showed im-
proved blood pressure after transplantation (125). 
Improved blood pressure was defined as the ability 
to reduce antihypertensive drug treatment after renal 
transplantation. These results suggest that while 
renal transplantation seems to have some beneficial 
outcomes, it is not sufficient to eradicate the hy-
pertension in ADPKD patients. In an observational 
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study on 312 children with ADPKD, it is further 
reported that high blood pressure promotes a faster 
renal volume growth (126). ADPKD children with 
high blood pressure have faster renal growth than 
those with lower blood pressure. This suggests that 
hypertension is a risk factor independent from kidney 
function in ADPKD. Hence, therapeutic interven-
tions in controlling blood pressure remain necessary 
and beneficial for ADPKD patients, regardless of 
kidney function or transplant.
Novel therapy
Although ciliary therapy does not exist today, it is 
appealing and tempting to speculate the possibility 
of treatment for localized blood vessel injuries such 
as aneurysm, atherosclerosis, dissection, edema, 
hemorrhage, and vascular ectasia, among others 
in ADPKD. In particular, endothelium-dependent 
relaxation is impaired, and endothelial nitric oxide 
synthase activity is decreased in patients with 
ADPKD (63, 69, 127). The endothelial dysfunction 
due to impaired release of NO in ADPKD patients 
becomes a crucial pathogenesis of hypertension. 
The imbalance in endothelium-derived vasoactive 
mediators might therefore need to be considered 
seriously in ADPKD patients (70, 128).
Of particular interest is a high level of poly-
cystin expression in the vascular system, which is 
required for the structural integrity of blood vessels 
(72, 129-131). The expression of polycystins in 
human endothelial cilia further provides a critical 
link between cilia and the vasculature (20, 25, 89). 
Although there are only limited reports on ciliary 
polycystins in vascular endothelial cells, abnormal 
expressions of polycystins are known to prevent 
normal cilia function that converts changes in fluid 
flow into biosynthesis of NO in interlobar arteries 
obtained from ADPKD patients (20).
Interestingly, changes in extracellular fluid 
flow can either activate or inactivate cilia function 
through polycystin-1 and polycystin-2 complex (25). 
A sudden increase in blood flow, as seen in daily fluc-
tuation of blood pressure, would activate cilia through 
polycystin complex. This, in turn, would allow calcium 
influx and initiate a series of biochemical cascades that 
lead to NO production (Figure 3). NO is a very potent 
physiological vasodilator that would decrease the 
baseline tension (contraction) of the vessel, and thus 
decrease vascular pressure. Subsequently, the dilation 
of the vessel during a sudden increase in blood pressure 
is a necessary local regulation to avoid focal injury of 
the blood vessel.
On the other hand, prolonged exposure to higher blood 
flow as seen in chronic hypertension would inactivate 
cilia by down-regulating functional polycystin-1 (25). 
Functional polycystin-1 as a mechanosensory molecule 
can be inactivated by proteolytic cleavage after expo-
sure to high fluid-shear stress. This may further suggest 
that in patients with high blood pressure, cilia would 
very unlikely sense minute changes in blood pressure, 
which might result in failure to provide a mechanism to 
autoregulate the local circulatory system. In addition, 
the presence of cilia in vascular smooth muscle cells 
has also been reported, and sensory polycystin-1 and 
polycystin-2 complex is localized in the cilia (132). Al-
though their roles are not clear at present, the vascular 
cilia are positioned in such a way that they maintain 
a specific alignment with respect to the lumen of the 
artery. Further studies of the role of this alignment may 
be necessary to shed light on their possible functions 
with regard to vascular hypertension.
Current clinical trial in hypertensive ADPKD
There is a wealth of evidence to indicate that ag-
gressive blood pressure control in ADPKD patients 
is a clinical necessity, regardless of kidney function. 
Drugs that inhibit the RAAS might be beneficial in 
this context. However, more robust clinical studies 
are essential to improve clinical outcomes with 
greater certainty. In particular, we need a more 
comprehensive clinical study to provide a greater 
number of subjects, longer follow-up time with 
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clear primary endpoints, and assessment of PKD1 
or PKD2 mutation either through sequence analysis 
or radiological imaging studies (133). An example 
of such a comprehensive study that is currently 
underway is HALT Progression of Polycystic Kid-
ney Disease (HALT PKD), which is a clinical trial 
evaluating the effectiveness of inhibiting RAAS in 
blood pressure control. The study will also deter-
mine whether a combined therapy of an ACE-I and 
an ARB would be superior than monotherapy ACE-I 
alone to delay the progression of renal disease and 
whether a more “rigorous” blood pressure (<110/75) 
would be more effective than standard blood pres-
sure target (<130/80) in preserving renal function 
(5). There is certainly much work remaining, and 
we are on the verge of conjuring and applying our 
concept and understanding of ADPKD for a better 
clinical practice and patient outcomes.
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